Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort

Liam G Heaney, Luis Perez de Llano, Mona Al-Ahmad, Vibeke Backer, John Busby, Giorgio Walter Canonica, George Christoff, Borja G. Cosio, J. Mark FitzGerald, Enrico Heffler, Takashi Iwanaga, David J Jackson, Andrew Menzies-Gow, Nikolaos G Papadopoulos, Andriana I. Papaioannou, Paul E Pfeffer, Todor A Popov, Celeste M. Porsbjerg, Chin Kook Rhee, Mohsen SadatsafaviYuji Tohda, Wang Eileen, Michael E Wechsler, Marianna Alacqua, Alan Altraja, Leif Bjermer, Unnur S. Björnsdóttir, Arnaud Bourdin, Guy Brusselle, Roland Buhl, Richard W Costello, Mark Hew, Mariko Koh Siyue, Sverre Lehmann, Lauri Lehtimäki, Matthew Peters, Camille Taillé, Christian Taube, Trung N Tran, Trung N Tran, Lakmini Bulathsinhala, Victoria A Carter, Isha Chaudhry, Nevaashni Eleangovan, Naeimeh Hosseini, Marjan Kerkhof, Ruth B Murray, Chris Price, David Price* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

98 Citations (Scopus)
6 Downloads (Pure)


Background: Phenotypic characteristics of eosinophilic and non-eosinophilic asthma patients are not well-characterized in global, real life severe asthma cohorts.Research Question: What is the prevalence of eosinophilic and non-eosinophilic phenotypes in thesevere asthma population, and can they be differentiated by clinical and biomarker variables?Study Design and Methods: This was an historical, registry study. Adult severe asthma patients with available blood eosinophil count (BEC) from 11 countries enrolled into the International SevereAsthma Registry (01/01/2015 to 09/30/2019) were categorized according to likelihood of eosinophilic phenotype using a pre-defined gradient eosinophilic algorithm based on highest BEC, long-term oral corticosteroid use, elevated fractional exhaled nitric oxide, nasal polyps, and adult onset asthma. Demographic/clinical characteristics were defined at baseline (i.e. 1-year prior or closest to date of BEC).Results: 1,716 patients with prospective data were included; 83.8% were identified as “most likely”(Grade 3), 8.3% were “likely” (Grade 2), and 6.3% “least likely” (Grade 1) to have an eosinophilic phenotype. 1.6% of patients had a non-eosinophilic phenotype (Grade 0). Eosinophilic phenotype patients (i.e. Grade 2 or 3) had later asthma onset (29.1 vs 6.7 yrs; p<0.001), and worse lung function (post-bronchodilator % predicted FEV1: 76.1% vs 89.3%; p=0.027) than those with a non-eosinophilic phenotype. Non-eosinophilic-phenotype patients were more likely to be female (81.5% vs 62.9%; p=0.047), have eczema (20.8% vs 8.5%; p=0.003) and use anti-IgE (32.1% vs 13.4%; p=0.004) andleukotriene receptor antagonists (50.0% vs 28.0%; p=0.011) add-on therapy.Interpretation: According to this multi-component, consensus-driven, and evidence-based eosinophil gradient algorithm (using variables readily accessible in real life), the severe asthma eosinophilic phenotype was more prevalent than previously identified, and phenotypically distinct. This pragmatic gradient algorithm utilizes variables readily accessible in primary and specialist care,Characterization of eosinophilic and non-eosinophilic severe asthma phenotypes addressing inherent issues of phenotype heterogeneity and phenotype instability. Identification oftreatable traits across phenotypes should improve therapeutic precision.
Original languageEnglish
Pages (from-to)814-830
Number of pages17
Issue number3
Early online date19 Apr 2021
Publication statusPublished - 1 Sept 2021

Bibliographical note

FUNDING/SUPPORT: This study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was partially funded by Optimum Patient Care Global and AstraZeneca Ltd. No funding was received by the OPRI for its contribution.


  • International Severe Asthma Registry
  • Europe
  • North America
  • Asia
  • Middle East


Dive into the research topics of 'Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort'. Together they form a unique fingerprint.

Cite this